Simcyp Limited Acquired by Certara

SHEFFIELD, England--(BUSINESS WIRE)-- Simcyp Limited announces its acquisition (subject to certain closing conditions) by Certara, a leading provider of drug discovery and development software and scientific consulting services. The acquisition makes Simcyp the third member of the Certara group alongside Tripos and Pharsight.

Simcyp will operate as a business unit within Certara maintaining its Consortium business model and its focus on population-based PBPK/PD modelling and simulation services and software which it provides to the industrial pharmaceutical community.

The acquisition will significantly strengthen Simcyp's ability to relate molecular structure to drug disposition through collaborative links with Tripos and extend Simcyp's reach into clinical trial simulation, IVIVC and PK/PD modelling and simulation through collaborative links with Pharsight.

As a Certara company, Simcyp becomes an integral part of the Certara vision to provide a ?joined-up' drug-development information/modelling and simulation platform that will help drive-up efficiencies in R&D and drive-down operating costs within their global pharmaceutical industry clients.

In making the announcement, John Evans, Managing Director at Simcyp said: "We're very pleased to become part of the Certara team. The acquisition by Certara will allow Simcyp to focus on its core competence whilst allowing us to draw on the broader drug development expertise available within the Certara family. Clients from across the spectrum of drug discovery and development will have access to a broader range of products and services, which will be enhanced by combining the attributes of Tripos, Simcyp, and Pharsight science and functionality."

Certara's President and Chief Executive Officer, Jim Hopkins, said: "We're excited to add Simcyp to the Certara family, as a complement to Pharsight and Tripos. With the capabilities offered by Simcyp's proprietary technology, combined with our existing software products and scientific consulting services, we expect to provide significant synergies to our mutual clients. From a translational science perspective, Simcyp's preclinical simulation technologies, which include prediction of drug/drug interactions, fit perfectly between Certara's existing discovery and clinical research offerings, thus enabling an end-to-end solution."

The shareholders of Simcyp were advised by Livingstone Partners, the international mid-market corporate finance advisory firm with offices in London and Chicago, and by DLA Piper one of the UK's leading law firms.

About Certara

Certara? is dedicated to improving human health through a broad spectrum of software products and services, from molecular discovery through clinical development, with special focus on supporting translational approaches to drug development. Certara was formed by uniting industry leaders Tripos®, provider of innovative scientific software solutions and services enabling life science researchers to improve the efficiency of molecular discovery, with Pharsight Corporation, provider of software and scientific consulting services to improve productivity and decision-making in preclinical and clinical drug development. Each Certara family brand has a primary focus on a key phase within the drug discovery and development process; combined, they offer a unique set of capabilities for modeling, analysis, and simulation and scientific informatics that can enable the cross-disciplinary approaches necessary for translational science initiatives. For more information, visit www.certara.com.

About Simcyp

As a Certara portfolio company, Simcyp will continue to provide platforms for the modelling and simulation of pharmacokinetics and pharmacodynamics in virtual human populations and virtual laboratory animals (rat, dog & mouse). The technology allows pharmaceutical researchers to predict in vivo outcomes from routinely generated in vitro data, to fit Simcyp models to observed clinical data and to assess inter-individual variability through ?real-life' simulations. This informs decision-making in drug development.

Simcyp will also continue providing expert consultancy services, run educational workshops and support academic and drug regulatory research through the provision of not-for-profit simulator licenses. For further information please visit www.simcyp.com.

Representatives from Simcyp Limited are available on request.